According to sources, US authorities are set to unveil the first charges in a probe of price fixing in the generic drug sector, Bloomberg reported Tuesday.
The people noted that at least two companies, as well as executives, will be indicted in the coming months, while a third firm could plead guilty to charges.
The probe, which began in 2014, has grown to include nearly every major generic firm including Mylan and Teva.
Perrigo previously acknowledged that its offices were raided by authorities in 2016, while people familiar with the matter also revealed that prosecutors searched Mylan's offices last year.
No charges have been filed in the investigation since the former CEO and president of Heritage Pharmaceuticals pleaded guilty in 2016 to conspiring with other companies to fix the prices of doxycycline and glyburide.
Shares in Mylan fell 1.5 percent on the news, while shares in Perrigo and Teva were down as much as 1.7 percent and 1.6 percent, respectively.
To read more NewsPoints articles, click here.